DDInter1725 DDInter1435
Sulfasalazine is an anti-inflammatory drug structurally related to salicylates and other non-steroidal anti-inflammatory drugs. It is indicated for managing inflammatory diseases such as ulcerative colitis and rheumatoid arthritis (RA).[L39065, A255582] Metabolized by intestinal bacteria, sulfasalazine is broken down into [mesalazine] and [sulfapyridine], 2 compounds that carry out the main pharmacological activity of sulfasalazine. Sulfasalazine was first used in 1940 for rheumatic polyarthritis, and has been firmly established itself as one fo the most useful disease-modifying antirheumatic drug (DMARD). Compared to the first line treatment of RA like methotrexate, sulfasalazine is almost as efficacious as methotrexate although with slightly less tolerability. However, sulfasalazine has less teratogenic side effects and faster onset of action compared to conventional DMARD. Sulf
Pexidartinib is a selective tyrosine kinase inhibitor that works by inhibiting the colony-stimulating factor (CSF1)/CSF1 receptor pathway. Pexidartinib was originally developed by Daiichi Sankyo, Inc. and it was approved by the FDA in August 2019 as the first systemic therapy for adult patients with symptomatic tenosynovial giant cell tumor. Tenosynovial giant cell tumor is a rare form of non-malignant tumor that causes the synovium and tendon sheaths to thicken and overgrow, leading to damage in surrounding joint tissue.[A182240,L7901] Debilitating symptoms often follow with tenosynovial giant cell tumors, along with a risk of significant functional limitations and a reduced quality of life in patients. While surgical resection is a current standard of care for tenosynovial giant cell tumor, there are tumor types where surgeries are deemed clinically ineffective with a high risk of lifetime recurrence. Pexidartinib works by blocking the immune responses that are activated in tenosynovial giant cell tumors. In clinical trials, pexidartinib was shown to promote improvements in patient symptoms and functional outcomes in TGCT. Pexidartinib is available in oral formulations and it is commonly marketed as Turalio.
Sulfasalazine {u} (Compound) resembles {v} (Compound) Olsalazine
Sulfasalazine {u} (Compound) resembles {v} (Compound) Balsalazide
Sulfasalazine {u} (Compound) treats {v} (Disease) ankylosing spondylitis
Sulfasalazine {u} (Compound) binds {v} (Gene) SLC46A1
Sulfasalazine {u} (Compound) upregulates {v} (Gene) GPATCH8
Sulfasalazine {u} (Compound) is included by {v} (Pharmacologic Class) Aminosalicylic Acids
Sulfasalazine {u} (Compound) downregulates {v} (Gene) ITGAE
Sulfasalazine {u} may cause a minor interaction that can limit clinical effects when taken with {v} Levomefolic acid
Sulfasalazine {u} may cause a minor interaction that can limit clinical effects when taken with {v} Folic acid
Sulfasalazine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Asparaginase Escherichia coli
Sulfasalazine (Compound) resembles Olsalazine (Compound)
Sulfasalazine (Compound) resembles Balsalazide (Compound)
Sulfasalazine (Compound) treats ankylosing spondylitis (Disease)
Sulfasalazine (Compound) binds SLC46A1 (Gene)
Sulfasalazine (Compound) upregulates GPATCH8 (Gene)
Sulfasalazine (Compound) is included by Aminosalicylic Acids (Pharmacologic Class)
Sulfasalazine (Compound) downregulates ITGAE (Gene)
Sulfasalazine may cause a minor interaction that can limit clinical effects when taken with Levomefolic acid
Sulfasalazine may cause a minor interaction that can limit clinical effects when taken with Folic acid
Sulfasalazine may cause a moderate interaction that could exacerbate diseases when taken with Asparaginase Escherichia coli